Exchanges: NASDAQ | NYSE | XLON | AMS | ADS | TSE | BRU

Financial News Feed

Alimera Sciences, Inc. (NASDAQ:ALIM) Q1 2019 Earnings Conference Call April 30, 2019 09:00 AM ET Company Participants Scott Gordon - President of Core IR Rick E

Read more

Shares of Alimera Sciences Inc (ALIM) are on watch as the Tenkan Line has moved below the Kijun line, indicating negative momentum for the equity. Alimera Sciences Inc moved 0.00 in the most recent se

Read more

Alimera Sciences Inc (ALIM) are in focus as we look at near-term expected movement. The reading from the 40-day commodity channel index is currently Hold. The CCI indicator is mainly used to identify

Read more

Alimera Sciences, Inc. (NasdaqGM:ALIM) has an ERP5 rank of 17233. The ERP5 Rank is an investment tool that analysts use to discover undervalued companies. The ERP5 looks at the Price to Book ratio, Ea

Read more

Foster & Motley Inc increased Prologis (PLD) stake by 121.38% reported in 2018Q4 SEC filing. Foster & Motley Inc acquired 9,930 shares as Prologis (PLD)’s stock rose 4.44%. The Foster & Motley Inc h

Read more

Scholtz & Company Llc increased Abbott Laboratories (ABT) stake by 18.07% reported in 2018Q4 SEC filing. Scholtz & Company Llc acquired 10,087 shares as Abbott Sentiment for Alimera Sciences Inc (ALIM

Read more

Tracking some historical stock price data for Alimera Sciences, Inc. (NASDAQ:ALIM), we note that performance has been positive over the last 52-week period. During that time, the stock has risen 1.92%

Read more

Examining shares of Alimera Sciences Inc (ALIM), we have seen that the Parabolic SAR is currently above the stock price. Traders tracking this signal may be on the lookout for a possible momentum dire

Read more

Alimera Sciences (NASDAQ:ALIM)‘s stock had its “buy” rating reiterated by HC Wainwright in a research note issued to investors on Tuesday. They currently have a $2.75 target price on the biophar

Read more

After a recent market scan, we can see that Alimera Sciences Inc (ALIM) shares have moved 1.82% higher over the past month. Tracking performance over the last 5 sessions, shares have moved 0.90%. Over

Read more

With a beta of 2.26, Alimera Sciences, Inc. (NASDAQ:ALIM) has a current analyst price target of 2.8 and touched 1.12 on a recent bid. Shares have performed 55.97% year to date and the 80.99 market cap

Read more

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank